Plasma for fractionation: South African Plasma Requirements

Size: px
Start display at page:

Download "Plasma for fractionation: South African Plasma Requirements"

Transcription

1 Plasma for fractionation: South African Plasma Requirements Dr Jeh-han Omarjee Head: Microbiological Sciences NBI is a "not for profit" company committed to providing safe, cost effective, quality medicinal products

2 Industry NBI Profile Industry Profile Not-for-Profit, public benefit organisation Registered as a Pharmaceutical Manufacturer Schedule 4 medicines (prescription only) Registered with the Medicines Control Council (SA) Operate in strategic association with BTS in SA Largest biotechnology company in SA

3 British Pharmacopoeia Council of Europe Blood Directive Plasma Quality Requirements WHO Annex 2 &4 Annexure 14 MCC guide

4 Process towards approving a blood establishment for the supply of plasma for fractionation

5 PAPER BASED AUDIT

6 Minimum information requested from blood establishment Regulatory framework of blood transfusion service National standards for blood transfusion Quality Management System

7 Organisation and personnel Reporting system Documentation Internals audits Change control Systems Storage and Transport Quality Management System Equipment Validation Materials Viral marker testing Critical Computerized systems Quality Control and monitoring data

8 Minimum information requested from blood establishment Regulatory framework of blood transfusion service National standards for blood transfusion Quality Management System Donor selection

9 Donor Selection Measures to exclude infectious donations Positive identification of donors Exclusion criteria Donors Selection criteria VNRD Records and traceability of donors

10 Minimum information requested from blood establishment Regulatory framework of blood transfusion service National standards for blood transfusion Quality Management System Donor selection Blood collection

11 Blood collection Blood/plasma collection process Blood bags used and anti-coagulant Procedure of collection Labelling of units and samples Volume of blood /plasma collected Mixing Reconciliation

12 Minimum information requested from blood establishment Regulatory framework of blood transfusion service National standards for blood transfusion Quality Management System Donor selection Blood collection Blood processing into components (plasma)

13 Plasma Processing Premises-storagetransport Storage after Processing below -20 C or colder Storage facilities, validation, segregation procedures Holding of blood units Plasma frozen within 24hrs of collection Release of plasma Method of separation of plasma from RBC Freezing of plasma, method, freeze rate, impact of containers Packaging and Transportation

14 Minimum information requested from blood establishment Regulatory framework of blood transfusion service National standards for blood transfusion Quality Management System Donor selection Blood collection Blood processing into components (plasma) Testing of blood products

15 Testing of blood products Screening of blood/plasma for infectious markers Screening tests (HBsAg, anti-hiv anti-hcv) and assay validation Nucleic acid testing and assay validation Test kits Quality control of screening Systems in place to control the labelling, testing and the release of compliant plasma units Retention of samples (storage and temperature) Lookback

16 Minimum information requested from blood establishment Regulatory framework of blood transfusion service National standards for blood transfusion Quality Management System Donor selection Blood collection Blood processing into components (plasma) Testing of blood products Epidemiology data (HIV, HBV and HCV) and emerging diseases

17 Epidemiology data of donor population Request epidemiology data for the previous 2-3 years Analyse and review data based on screening tests Determine incidence and prevalence rates Residual risk

18 PHYSICAL AUDIT

19 Key criteria that will be assessed Compliance with the principles of GMP QMS system is established Compliance with standards A system that is operational for the issue of good quality and safe plasma

20 Paper audit Road Map to approval Physical audit Final approval from the MCC

21 NBI s Other Plasma Quality requirements Once supplier is approved

22 Artificial mini-pool testing Hepatitis A and Hepatitis E virus (non-lipid enveloped virus) Parvovirus B19 (<log4 IU/ml) Major GMP breakthroughs

23 Plasma Consignment

24 LIMS as the sentinel Plasma Reconciliation

25

26 Q-ARM Artificial Pool testing (APT/mini-pool testing)

27 Artificial mini pool testing Inventory 40 Plasma boxes Verification and reconciliation of donations Removal of donation segments X 36 donations Pooling of donation segments for each box creating BOX POOLS Quality Assurance Packaging Manufacturing + Column 1 Column 2 Column 3 Column 4 Column 5 Row A B B B B B Row B B B B B B Row C B B B B B Row D B B B B B Row E B B B B B Row F B B B B B NAT and Serology Row G B B B B B Row H B B B B B HAV RNA and HEV RNA Positive

28 NBI s Other Plasma Quality requirements An electronic system to issue plasma to fractionator Plasma Master File

29 Plasma Master File (PMF) PMF is a compilation of all scientific data on quality and safety of plasma Request information to compile the PMF Plasma Origin Plasma Quality and Safety Epidemiology data The data is requested and reviewed annually

30 Thank You Office hours: +27 (0) Website:

TGA regulation of local manufacturers of plasma derivatives CSL Behring Australia s overview

TGA regulation of local manufacturers of plasma derivatives CSL Behring Australia s overview IPFA Workshop Session 7: REGULATORY CONSIDERATIONS TGA regulation of local manufacturers of plasma derivatives CSL Behring Australia s overview Mary Lavithis, CSL Behring Australia Presented at: IPFA Asia

More information

QSEAL Recovered Plasma Specification

QSEAL Recovered Plasma Specification QSEAL Recovered Plasma Specification Background The is part of a series of standards that comprise the Plasma Protein Therapeutics Association (PPTA) QSEAL Standards Program. PPTA's Voluntary Standards

More information

Guide to the preparation, use and quality assurance of blood components

Guide to the preparation, use and quality assurance of blood components Contents Foreword...3 Members of the European Committee (Partial Agreement) on Blood Transfusion... 8 Members of the GTS working group... 22 Members of the TS066 working group... 30 Recommendation No.

More information

GMP IN BLOOD ESTABLISHMENTS: A BASIC ELEMENT FOR PLASMA QUALITY

GMP IN BLOOD ESTABLISHMENTS: A BASIC ELEMENT FOR PLASMA QUALITY GMP IN BLOOD ESTABLISHMENTS: A BASIC ELEMENT FOR PLASMA QUALITY Dr. Christian Schärer Swissmedic, Swiss Agency for Therapeutic Products Inspectorates, Hallerstrasse 7 CH-3000 Bern 9 christian.schaerer@swissmedic.ch

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components (including Source Plasma and Source Leukocytes) to Adequately and Appropriately

More information

Plasma Fractionation Issues for Developing Countries DR YASMIN AYOB

Plasma Fractionation Issues for Developing Countries DR YASMIN AYOB Plasma Fractionation Issues for Developing Countries DR YASMIN AYOB Plasma Fractionation Evolved from a medical service to a global manufacturing industry Involves sophisticated industrial process High

More information

Source Plasma Safety

Source Plasma Safety Source Plasma Safety Plasma May 15-19, 2017 George Schreiber, ScD, PPTA Director, Epidemiology Three components: Plasma Product Safety Donor Quality Manufacturing Pool Quality Fractionation Process Safe

More information

2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies

2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies 2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies Submitted by: Malaysia Policy Dialogue and Workshop on Attaining a Safe and Sustainable Blood Supply Chain Manila, Philippines 30 September 1

More information

The testing of Donated Blood and Components at NHSBT

The testing of Donated Blood and Components at NHSBT The testing of Donated Blood and Components at NHSBT NHSBT is responsible for collecting all donated blood and platelets in England, then processing into components before issuing to client hospitals.

More information

INDONESIAN EXPERIENCE IN PRODUCING MINIPOOL CRYOPRECIPITATE. Yuyun SM Soedarmono

INDONESIAN EXPERIENCE IN PRODUCING MINIPOOL CRYOPRECIPITATE. Yuyun SM Soedarmono INDONESIAN EXPERIENCE IN PRODUCING MINIPOOL CRYOPRECIPITATE Yuyun SM Soedarmono 1 BACKGROUND Indonesia has more than 240 million population and approximately 25,000 hemophilia A patients Hemophilia A patients

More information

Screening donors and donations for transfusion transmissible infectious agents. Alan Kitchen

Screening donors and donations for transfusion transmissible infectious agents. Alan Kitchen Screening donors and donations for transfusion transmissible infectious agents Alan Kitchen Aim Not to teach you microbiology To provide and awareness of the big picture To provide an understanding of

More information

Il ruolo delle VEQ per la sicurezza trasfusionale

Il ruolo delle VEQ per la sicurezza trasfusionale Il ruolo delle VEQ per la sicurezza trasfusionale The role of EQA for transfusion safety Giulio Pisani CNCF Ist. Sup. Sanità Global Blood Product Safety, Roma 10 aprile 2019 Blood transfusion is an essential

More information

DONOR RECRUITMENT AND PLASMA COLLECTION IN INDONESIA. Yuyun SM Soedarmono Blood Services Committee Ministry of Health of Indonesia 1

DONOR RECRUITMENT AND PLASMA COLLECTION IN INDONESIA. Yuyun SM Soedarmono Blood Services Committee Ministry of Health of Indonesia 1 DONOR RECRUITMENT AND PLASMA COLLECTION IN INDONESIA Yuyun SM Soedarmono Blood Services Committee Ministry of Health of Indonesia 1 OUTLINE Introduction Challenges to Fulfill Global Demand of Plasma for

More information

Impact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013

Impact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013 Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013 Overview of SANBS SANBS is a private not for profit company

More information

15. Procuring, processing and transporting gametes and

15. Procuring, processing and transporting gametes and 15. Procuring, processing and transporting gametes and embryos Version 6.0 On this page: : Extracts from the HFE Act Directions HFEA guidance: Documented procedures: general Patient selection and procurement

More information

Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey

Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey This questionnaire consists of three sections: A. Collection and

More information

EC CERTIFICATE. National Institute for Biological Standards and Control (NIBSC) Blanche Lane South Mimms Potters Bar Hertfordshire EN6 3QG UK

EC CERTIFICATE. National Institute for Biological Standards and Control (NIBSC) Blanche Lane South Mimms Potters Bar Hertfordshire EN6 3QG UK National Institute for Biological Standards and Control (NIBSC) EC Certificate - Full Quality Assurance System Approval Certificate Annex IV (excluding sections 4 and 6) of Council Directive 98/79/EC on

More information

The establishment of well-organized, nationally-coordinated blood transfusion services with quality systems in all areas

The establishment of well-organized, nationally-coordinated blood transfusion services with quality systems in all areas Blood Safety Global Database on Blood Safety (GDBS) 2013 The World Health Organization (WHO) programme on Blood Transfusion Safety would appreciate your kind cooperation in completing this data collection

More information

Draft Agreed by Biologics Working Party December Draft Agreed by Blood Products Working party December 2010

Draft Agreed by Biologics Working Party December Draft Agreed by Blood Products Working party December 2010 15 December 2011 EMA/CHMP/BWP/360642/2010 rev. 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the warning on transmissible agents in summary of product characteristics (SmPCs) and

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Advisement for the Use of Gen-Probe Procleix Ultrio Plus Assay for NAT Testing on Cadaveric Donors Release Date: 08/03/14 American Medical Education and Research Association 4757

More information

Lookback studies to assess viral risks The French experience

Lookback studies to assess viral risks The French experience Lookback studies to assess viral risks The French experience 2000-2012 S Laperche 1, MF Leconte des Floris 2, J Pillonel 3, L Hauser 2, C Lefort 2, JY Py 2, I Hervé 2, R Djoudi 2 For the French haemovigilance

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 21 September 2006 EMEA/CHMP/BWP/298390/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON

More information

BLOOD SAFETY STATUS IN INDONESIA. Yuyun Soedarmono Chairman of the Indonesian Association of Transfusion Medicine

BLOOD SAFETY STATUS IN INDONESIA. Yuyun Soedarmono Chairman of the Indonesian Association of Transfusion Medicine BLOOD SAFETY STATUS IN INDONESIA Yuyun Soedarmono Chairman of the Indonesian Association of Transfusion Medicine OUTLINE Background Blood services in Indonesia Regulation related to blood safety in Indonesia

More information

Jovona Powelson, B.S. MLT (ASCP) Director of Laboratories

Jovona Powelson, B.S. MLT (ASCP) Director of Laboratories Jovona Powelson, B.S. MLT (ASCP) Director of Laboratories Blood Products From the Donor to You Objectives Deliver a brief virtual tour of a blood center. Describe the number of donors needed to meet the

More information

Using Donor Human Milk in Extremely Premature Infants

Using Donor Human Milk in Extremely Premature Infants Using Donor Human Milk in Extremely Premature Infants Introduction Scott Eaker, Vice President of Quality and Regulatory Affairs Scott Elster, Chief Executive Officer David Rechtman, MD, Chief Medical

More information

HUNGARIAN NATIONAL BLOOD TRANSFUSION SERVICE. Dr. Klara Baroti-Tóth, PhD IPFA/PEI 19 th International Workshop Budapest, May, 2012.

HUNGARIAN NATIONAL BLOOD TRANSFUSION SERVICE. Dr. Klara Baroti-Tóth, PhD IPFA/PEI 19 th International Workshop Budapest, May, 2012. HUNGARIAN NATIONAL BLOOD TRANSFUSION SERVICE Dr. Klara Baroti-Tóth, PhD IPFA/PEI 19 th International Workshop Budapest, 23-24 May, 212. BLOOD DONATION G I V I N G I S G O O D ORGAN COORDINATION OFFICE

More information

L 256/32 Official Journal of the European Union

L 256/32 Official Journal of the European Union L 256/32 Official Journal of the European Union 1.10.2005 COMMISSION DIRECTIVE 2005/61/EC of 30 September 2005 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards

More information

Impact of donor epidemiology and screening strategies on the safety of blood and plasma for fractionation

Impact of donor epidemiology and screening strategies on the safety of blood and plasma for fractionation IPFA 2 nd Asia Workshop in Yogyakarta Impact of donor epidemiology and screening strategies on the safety of blood and plasma for fractionation Yoshihiko Tani, MD, PhD Japanese Red Cross Osaka Blood Center

More information

IQPP Qualified Donor Standard

IQPP Qualified Donor Standard IQPP Qualified Donor Standard Background The is part of a series of standards that comprise the Plasma Protein Therapeutics Association (PPTA) IQPP Standards Program. PPTA's Voluntary Standards Program

More information

TRANSFUSION ASSOCIATED DISEASE, RECALL, OR COMPLICATION INVESTIGATION POLICY I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION:

TRANSFUSION ASSOCIATED DISEASE, RECALL, OR COMPLICATION INVESTIGATION POLICY I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION: I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION: A. TRANSFUSION RELATED FATALITY: FDA and MEDIC must be notified immediately, and subsequently in writing, when a possible transfusion related

More information

HEPATITIS SCREENING IN THE LITHUANIAN BLOOD ESTABLISHMENTS. Joana Bikulčienė Director of National blood center

HEPATITIS SCREENING IN THE LITHUANIAN BLOOD ESTABLISHMENTS. Joana Bikulčienė Director of National blood center HEPATITIS SCREENING IN THE LITHUANIAN BLOOD ESTABLISHMENTS Joana Bikulčienė Director of National blood center j.bikulciene@kraujodonoryste.lt Organizational structure of Lithuanian blood service 1 specialized

More information

Human Hepatitis B Immunoglobulin, solution for intramuscular injection.

Human Hepatitis B Immunoglobulin, solution for intramuscular injection. New Zealand Data Sheet Hepatitis B Immunoglobulin-VF NAME OF THE MEDICINE Human Hepatitis B Immunoglobulin, solution for intramuscular injection. DESCRIPTION Hepatitis B Immunoglobulin-VF is a sterile,

More information

Hepa%%s E Virus Is it a Concern?

Hepa%%s E Virus Is it a Concern? IPFA/PEI 17 th Workshop on Surveillance and Screening of Blood Borne Pathogens 26-27 May 2010, The Regent Esplanade Zagreb Hotel, Zagreb, Croa%a Hepa%%s E Virus Is it a Concern? Keiji Matsubayashi Hokkaido

More information

donors and collecting blood and plasma in for-profit or a not for profit environment

donors and collecting blood and plasma in for-profit or a not for profit environment Remunerated versus non-remunerated donors and collecting blood and plasma in for-profit or a not for profit environment ISBT Amsterdam, June 4, 2013 Jan M. Bult President PPTA PATIENT CENTEREDNESS IT

More information

Database on Blood Safety 2009 in ECO Member States

Database on Blood Safety 2009 in ECO Member States Database on Blood Safety 2009 in ECO Member States Section 1: Administrative Information Information provided by: 1.1 Name: 1.2 Title: 1.3 Position: 1.4 Organization: 1.5 Address: 1.6 Country: 1.7 Tel.

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT. APPENDICES a TO GUIDELINE ON EPIDEMIOLOGICAL DATA ON BLOOD TRANSMISSIBLE INFECTIONS

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT. APPENDICES a TO GUIDELINE ON EPIDEMIOLOGICAL DATA ON BLOOD TRANSMISSIBLE INFECTIONS European Medicines Agency Evaluation of Medicines for Human Use London, 20 May 2009 Doc. Ref. EMEA/CPMP/BWP/125/04 Rev.1 Appendices COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT APPENDICES

More information

PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER

PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Verified with regard to factual content 13.12.2011 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER GAMMA anty-hbs 1000 Immunoglobulinum humanum hepatitidis B Human immunoglobulin against Hepatitis

More information

Annual SHOT Report 2016 Supplementary Information. Chapter 17: Transfusion-Transmitted Infections (TTI)

Annual SHOT Report 2016 Supplementary Information. Chapter 17: Transfusion-Transmitted Infections (TTI) Annual SHOT Report 2016 Supplementary Information Chapter 17: Transfusion-Transmitted s (TTI) The table below is an excerpt from the full Table 17.3 which can be viewed in the main report. Case reports

More information

A. Anti-HIV-1/2, HIV NAT Lookback: for those identified blood and blood components collected:

A. Anti-HIV-1/2, HIV NAT Lookback: for those identified blood and blood components collected: PURPOSE: MATERIALS: To outline a procedure for removing, recalling and/or correcting blood products that do not meet the requirements of the FDA, AABB, or the blood center. Recall/Market Withdrawal Form

More information

For information only: all participants in the graduated plan procedure. 7 January 2013

For information only: all participants in the graduated plan procedure. 7 January 2013 Paul-Ehrlich-Institut P.O. Box 63207 Langen, Germany To: All marketing authorisation holders of cellular blood products and therapeutic single plasma as well as holders of an authorisation for stem cells

More information

Chapter 17: Transfusion-Transmitted Infections (TTI)

Chapter 17: Transfusion-Transmitted Infections (TTI) Annual SHOT Report 2014 Supplementary Information Chapter 17: Transfusion-Transmitted s (TTI) The table below is an excerpt from the full Table 17.2 which can be viewed in the main report. Case reports

More information

Understanding your epidemic: WHO tools for hepatitis surveillance

Understanding your epidemic: WHO tools for hepatitis surveillance . Understanding your epidemic: WHO tools for hepatitis surveillance Dr Antons Mozalevskis / WHO Regional Office for Europe Dr Yvan Hutin / Global Hepatitis Programme, WHO Headquarters 25 October 2018,

More information

Impact of multi-dye multiplex technology on testing algorithm

Impact of multi-dye multiplex technology on testing algorithm Impact of multi-dye multiplex technology on testing algorithm Lydia Blanco. Mª Isabel Gonzalez-Fraile Centro de Hemoterapia y Hemodonación de Castilla y León, España TTI EPIDEMIOLOGICAL DATA IN SPAIN NAT

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Lookback for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test

More information

The New Regulations - Special IVD Issues

The New Regulations - Special IVD Issues The New Regulations - Special IVD Issues Dirk Stynen, Ph. D. President - Principal Consultant Qarad Geel, Belgium RMD Brussels October 2018 The IVD Regulation 2017/746 October 29, 2018 www.qarad.com 2

More information

WHO Parvovirus B19 Genotype Panel

WHO Parvovirus B19 Genotype Panel WHO Parvovirus B19 Genotype Panel Mei-ying W Yu, PhD SoGAT XXII Rome, 14-15 April 2011 1 st WHO International Reference Panel for Parvovirus B19 Genotypes In Oct 2009, a plasma-derived parvovirus B19 (B19V)

More information

Inspections, Compliance, Enforcement, and Criminal Investigations. Central Texas Regional Blood & Tissue Center 07-Nov-03

Inspections, Compliance, Enforcement, and Criminal Investigations. Central Texas Regional Blood & Tissue Center 07-Nov-03 1 of 7 6/10/2009 2:20 PM Inspections, Compliance, Enforcement, and Criminal Investigations Department of Health and Human Services Public Health Service Food and Drug Administration Dallas District 4040

More information

A comparison of the removal of parvovirus B19 and model parvoviruses from plasma products by virus filtration

A comparison of the removal of parvovirus B19 and model parvoviruses from plasma products by virus filtration A comparison of the removal of parvovirus B19 and model parvoviruses from plasma products by virus filtration Shirley Stagg, Samantha Fernando, Amy Shackell, Peter Roberts, Joan Dalton Bio Products Laboratory,

More information

National Screening laboratory Sanquin The use of NAT in blood donation screening in The Netherlands. TransMed conference Bhopal 18 November 2016

National Screening laboratory Sanquin The use of NAT in blood donation screening in The Netherlands. TransMed conference Bhopal 18 November 2016 Dr. Anton van Weert National Screening laboratory Sanquin The use of NAT in blood donation screening in The Netherlands TransMed conference Bhopal 18 Introduction Thank you! Anton van Weert, PhD, MBA Manager

More information

Structure and duties of Blood service

Structure and duties of Blood service NATIONAL CENTER FOR TRANSFUSION MEDICINE Prevalence of infectious diseases among Mongolian blood donors Namjil Erdenebayar General director of The National Center for Transfusion Medicine, Mongolia NCTM,

More information

For Research Use Only Ver

For Research Use Only Ver INSTRUCTION MANUAL Quick-RNA Viral Kit Catalog Nos. R1034 & R1035 Highlights Quick, spin-column purification of viral RNA from plasma, serum, CSF, cell culture media, cellular suspensions, urine, blood,

More information

Table 1: Organisations that commented on the draft Guideline as released for consultation

Table 1: Organisations that commented on the draft Guideline as released for consultation European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 21 September 2006 Doc. Ref. OVERVIEW OF COMMENTS RECEIVED ON DRAFT GUIDELINE ON VALIDATION OF IMMUNOASSAY FOR THE

More information

Overview of Blood Transfusion System of Iran:

Overview of Blood Transfusion System of Iran: Report Article Overview of Blood Transfusion System of Iran: 2002-2011 AM Cheraghali High Institute for Research and Education on Transfusion Medicine, Iran Blood Transfusion Organization and University

More information

Ensuring Compliance: Regulatory guidance for virus clearance validation

Ensuring Compliance: Regulatory guidance for virus clearance validation Application Note Ensuring Compliance: Regulatory guidance for virus clearance validation Introduction To assure virus safety of biological therapeutics, regulatory guidance advocates an approach in which

More information

AccuVert HBV Seroconversion Panel PHM941(M) ( )

AccuVert HBV Seroconversion Panel PHM941(M) ( ) PACKAGE INSERT PHM941(M) (0605-0061) INTENDED USE PHM941(M) (0605-0061) is a group of serial bleeds from an individual plasma donor during HBV seroconversion. This panel is intended for use by diagnostics

More information

to be notified: all parties involved in the graduated plan procedure. Annexes

to be notified: all parties involved in the graduated plan procedure. Annexes Paul-Ehrlich-Institut Postfach 63207 Langen, Germany To all marketing authorisation holders of cellular blood preparations and therapeutic single plasmas as well as authorisation holders of stem cells

More information

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P Record Status This is a critical abstract of an economic evaluation that meets

More information

EMEA WORKSHOP ON THE PLASMA MASTER FILE October 2001 REPORT

EMEA WORKSHOP ON THE PLASMA MASTER FILE October 2001 REPORT The European Agency for the Evaluation of Medicinal Products Pre-authorisation Evaluation of Medicines for Human Use London, 18 December 2002 Doc. Ref: EMEA/CPMP/BWP/1737/02 EMEA WORKSHOP ON THE PLASMA

More information

23 November Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

23 November Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852 23 November 2016 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Submitted via http://www.regulations.gov Re: Docket No. FDA-2016-N-1502,

More information

IPEC Europe Suggested Alternative (if none then original text is clear and needs no alteration) Purpose and Scope

IPEC Europe Suggested Alternative (if none then original text is clear and needs no alteration) Purpose and Scope IPEC Europe Observations and Recommendations on Guidelines On The Formalised Risk Assessment For Ascertaining The Appropriate Good Manufacturing Practice For Excipients Of Medicinal Products For Human

More information

APPROACH TO RISK MANAGEMENT IN MEDICAL PRACTICE: STANDPOINT OF THE BLOOD TRASFUSION*

APPROACH TO RISK MANAGEMENT IN MEDICAL PRACTICE: STANDPOINT OF THE BLOOD TRASFUSION* 11 APPROACH TO RISK MANAGEMENT IN MEDICAL PRACTICE: STANDPOINT OF THE BLOOD TRASFUSION* Hisami IKEDA** Asian Med. J. 44(1): 11 21, 2000 Abstract: In the field of blood transfusion, risk management is defined

More information

Instructions for Use (Version 3-14 th May 2003) Changes from previous version are shown in Red, deletions are shown as ^

Instructions for Use (Version 3-14 th May 2003) Changes from previous version are shown in Red, deletions are shown as ^ Page 1 of 5 Page 1 of 5, 97/656 WHO 1 st International Standard for HIV-1 RNA for Nucleic Acid-Based Techniques (NAT) NIBSC code: 97/656 Instructions for Use (Version 3-14 th May 2003) Changes from previous

More information

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int Part 1: General information Name of Manufacturer Prequalification Team WHO PUBLIC INSPECTION

More information

The Counselling of Blood Donors Identified as HIV Reactive. A Review as from January 2007 until June 2011

The Counselling of Blood Donors Identified as HIV Reactive. A Review as from January 2007 until June 2011 The Counselling of Blood Donors Identified as HIV Reactive A Review as from January 2007 until June 2011 The Blood Transfusion Service of Namibia Dr. Regine Redecker Mr. Tinus Matyayi 2 3 Background -TTI

More information

Duration: 12 months May to April

Duration: 12 months May to April SPECIALIST CERTIFICATE IN TRANSFUSION SCIENCE PRACTICE PROGRAMME OF STUDY OVERVIEW Example only Duration: 12 months May to April This document serves as a general programme overview only. To ensure you

More information

Prevention and control of hepatitis B and C in the European Region of WHO

Prevention and control of hepatitis B and C in the European Region of WHO Prevention and control of hepatitis B and C in the European Region of WHO Viral Hepatitis Prevention Board Dr Nedret Emiroglu WHO Regional Office for Europe Burden of viral hepatitis in the European Region

More information

Health Care Workers and Viral Hepatitis in Turkey. Bulent Degertekin M.D. Viral Hepatitis Prevention Board Meeting

Health Care Workers and Viral Hepatitis in Turkey. Bulent Degertekin M.D. Viral Hepatitis Prevention Board Meeting Different Aspects of Viral Hepatitis Health Care Workers and Viral Hepatitis in Turkey Bulent Degertekin M.D. Viral Hepatitis Prevention Board Meeting 12 13 November 2009 Istanbul. Turkey Hepatitis B and

More information

PHARMACOPOEIA MONOGRAPH

PHARMACOPOEIA MONOGRAPH MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION Human coagulation factor IX PHARMACOPOEIA MONOGRAPH PM.3.3.2.0004.15 First Edition The present Pharmacopoeia Monograph applies to human coagulation factor IX

More information

risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV)

risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV) Prevention and ResidualR risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV) Syria Laperche L (Centre National de référence r rence pour les hépatites h B et C en Transfusion)

More information

SOP 17 BLOOD BANK. 3. Overall Responsibility: Blood Bank In-Change/Pathologist.

SOP 17 BLOOD BANK. 3. Overall Responsibility: Blood Bank In-Change/Pathologist. SOP 17 BLOOD BANK 1. Purpose: To ensure the availability of safe blood unit with facility for compatibility testing, storage and issue of blood in an aseptic environment on 24*7 basis trough trained professionals.

More information

RECALL / EVENT INVESTIGATION & PATIENT LOOK BACK

RECALL / EVENT INVESTIGATION & PATIENT LOOK BACK RECALL / EVENT INVESTIGATION & PATIENT LOOK BACK Federal, State and AABB requirements for nonconforming product investigation and recipient look back for adverse impact Stacy Ralston MPH, CLS (ASCP), RAC

More information

Routine NAT-screening for West Nile Virus Infections in Germany: Being prepared

Routine NAT-screening for West Nile Virus Infections in Germany: Being prepared Routine NAT-screening for West Nile Virus Infections in Germany: Being prepared R. Thermann, W. K. Roth IPFA / PEI 18 th international workshop on Surveillance and screening of blood borne pathogens Budapest,

More information

Customer Service and Ordering Address Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands

Customer Service and Ordering Address Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands PRODUCT CATALOGUE Customer Service and Ordering Address Biologicals Quality Control B.V. Droogmakerij 31h 1851 LX Heiloo The Netherlands Communication +31 72 202 07 30 +31 72 202 07 31 sales@bioqcontrol.com

More information

Allergens Assessing risk and mapping your facility

Allergens Assessing risk and mapping your facility Allergens Assessing risk and mapping your facility Evaluate and mitigate your allergen risks Allergen mapping is a part of allergen risk assessment and is an effective tool to identify and track allergens

More information

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Schedule of Accreditation 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK National Infection Service, Public Health England Colindale 61 Colindale Avenue London NW9 5EQ Contact: Dr Sanjiv

More information

Objectives. Methods. Results. Economic

Objectives. Methods. Results. Economic Octaplas Compared with Fresh Frozen Plasma to Reduce the Risk of Transmitting Lipid-Enveloped Viruses: An Economic Analysis and Budget Impact Analysis [Adapted from Membe SK, Coyle D, Husereau D, Cimon

More information

Update on WHO Prequalification of In Vitro Diagnostics

Update on WHO Prequalification of In Vitro Diagnostics Update on WHO Prequalification of In Vitro Diagnostics Robyn Meurant and Mercedes Perez Gonzalez Prequalification Team Diagnostics Assessment Essential Medicines and Health Products World Health Organization

More information

Donor Screening in The Region. Vincini GA NRL, Melbourne, Australia

Donor Screening in The Region. Vincini GA NRL, Melbourne, Australia Donor Screening in The Region Vincini GA NRL, Melbourne, Australia NRL Established in 1985 Not-for-profit organisation that exists to support laboratories that perform testing for the diagnosis and management

More information

AKA Good Manufacturing Practice (GMP) Certification Program

AKA Good Manufacturing Practice (GMP) Certification Program AKA Good Manufacturing Practice (GMP) Certification Program Preamble The American Kratom Association (AKA) is establishing this program to assure the safety and integrity of kratom dietary supplements

More information

(DNA) Real-time PCR. Exicycler 96 Rotor-Gene Q/6000 PCR

(DNA) Real-time PCR. Exicycler 96 Rotor-Gene Q/6000 PCR Real-Time (DNA) Real-time Exicycler 96 Rotor-Gene Q/6000 IU Mix1 Mix2 IU/μl IU/μl IU/μl IU/μl IU/μl IPC NTC C 1 Lot# 2 Freeze & thawing 1 MSDS: Material Safety Data Sheets (TaqMan Real-time ' FAM ' BHQ1

More information

Instruction to implement measures for risk minimisation in using HIV-1 NAT test systems

Instruction to implement measures for risk minimisation in using HIV-1 NAT test systems Paul-Ehrlich-Institut P.O. Box 63207 Langen, Germany To: The marketing authorisation holders of cellular blood products and fresh frozen plasma and the holders of authorisations for stem cell preparations

More information

WHO Prequalification of In Vitro Diagnostics Programme

WHO Prequalification of In Vitro Diagnostics Programme WHO Prequalification of In Vitro Diagnostics Programme International HIV/Viral Hepatitis Co-Infection Satellite Meeting 19 July 2014, Melbourne Anita Sands Prequalification Diagnostics Team Department

More information

in pregnancy Document Review History Version Review Date Reviewed By Approved By

in pregnancy Document Review History Version Review Date Reviewed By Approved By GYNAECOLOGY/ ANTENATAL CARE WIRRAL WOMEN & CHILDREN S HOSPITAL Guideline No: Hepatitis B management in pregnancy VERSION 1 AMENDMENTS MADE: N/A DATE OF ISSUE: May 2012 DATE OF REVIEW: May 2015 REVIEW INTERVAL:

More information

The use of QCMD proficiency testing panels in clinical virology.

The use of QCMD proficiency testing panels in clinical virology. The use of QCMD proficiency testing panels in clinical virology. Prof.dr. Bert Niesters Department of Medical Microbiology Division of Clinical Virology UMC Groningen Disease Disease Management Viral Load

More information

Product Monograph. Key Scientific Information

Product Monograph. Key Scientific Information Product Monograph Key Scientific Information Ko ate -DVI (Double Viral Inactivation) Infusion of more than 2 billion IUs worldwide with no confirmed cases of viral transmission.* Talecris is a leader in

More information

EUROPEAN COMMISSION DIRECTORATE GENERAL FOR HEALTH AND FOOD SAFETY

EUROPEAN COMMISSION DIRECTORATE GENERAL FOR HEALTH AND FOOD SAFETY Ref. Ares(2016)5909621-13/10/2016 EUROPEAN COMMISSION DIRECTORATE GENERAL FOR HEALTH AND FOOD SAFETY Directorate B - Health systems, medical products and innovation B4 Medical products: quality, safety

More information

Armed Services Blood Program

Armed Services Blood Program Armed Services Blood Program Defense Health Board Concerns Regarding the Collection and Transfusion of Non-FDA Compliant Blood Products in Theater Information Brief Defense Health Board 17 August 2009

More information

Probability of false initial and repeat ID-NAT reactive donations. Marion Vermeulen IPFA Rome 2014

Probability of false initial and repeat ID-NAT reactive donations. Marion Vermeulen IPFA Rome 2014 Probability of false initial and repeat ID-NAT reactive donations Marion Vermeulen IPFA Rome 2014 Overview of SANBS SANBS is a non profit organization Provides a vein to vein blood transfusion service

More information

Help Thalassemia Child get Blood - Their Lifeline

Help Thalassemia Child get Blood - Their Lifeline Help Thalassemia Child get Blood - Their Lifeline Project Aarohi Blood Bank has undertaken to provide 200 blood transfusions per month free of charge to the children affected by Thalassemia, for a year,

More information

Global Reporting System for Hepatitis (GRSH) An introduction. WHO Global Hepatitis Programme

Global Reporting System for Hepatitis (GRSH) An introduction. WHO Global Hepatitis Programme Global Reporting System for Hepatitis (GRSH) An introduction WHO Global Hepatitis Programme 2018 Objectives 1. Explain the role of the new reporting system 2. Outline the reporting required from countries

More information

Maximizing Cornea and Tissue Donation through Specimen Quality

Maximizing Cornea and Tissue Donation through Specimen Quality Maximizing Cornea and Tissue Donation through Specimen Quality Robert W. Bresler, Sydney D. Gastreich, Elias G. Koulouriotis, Linda S. Martin, Susan Diane Brockmeier, Chak-Sum Ho, PhD Abstract Purpose:

More information

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: OraQuick HCV Rapid Antibody Test Kit WHO reference number: PQDx

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: OraQuick HCV Rapid Antibody Test Kit WHO reference number: PQDx WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT Product: OraQuick HCV Rapid Antibody Test Kit WHO reference number: PQDx 0244-055-00 OraQuick HCV Rapid Antibody Test Kit with product codes 1001-0270

More information

NAT Screening of Blood Donations in NBC, TRCS

NAT Screening of Blood Donations in NBC, TRCS IPFA/PEI, Italy NAT Screening of Blood Donations in NBC, TRCS 2000-2001 Clinical evaluation using COBAS AmpliiScreen HIV & HCV assays, (MP24) window period rate - 1 : 108,768 for HIV-1 and HCV 2002 Routine

More information

WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA

WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 21 October 2016 WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA

More information

STUDY PROTOCOL. CCQM-K139 and CCQM-P173. Elements in Human Serum

STUDY PROTOCOL. CCQM-K139 and CCQM-P173. Elements in Human Serum Ref. No.: CML-STY-0068A/01 STUDY PROTOCOL CCQM-K139 and CCQM-P173 Elements in Human Serum Introduction Elements in serum serve as important biomarkers and reflect the well-being of an individual. For example,

More information

Guideline on quality aspects on the isolation of candidate influenza vaccine viruses in cell culture

Guideline on quality aspects on the isolation of candidate influenza vaccine viruses in cell culture 11 July 2011 EMA/CHMP/BWP/368186/2011 Committee for Human Medicinal Products (CHMP) Guideline on quality aspects on the isolation of candidate influenza vaccine viruses in Draft Agreed by Biologics Working

More information

WHO/EHT/ Global Database on Blood Safety

WHO/EHT/ Global Database on Blood Safety WHO/EHT/4.9 Global Database on Blood Safety Report 21 22 Needs and challenges The need for a safe and adequate blood supply is universal. In countries with developed health care systems, blood and blood

More information

Comparability and quality of experimental data under different quality systems. S. Caroli Istituto Superiore di Sanità Rome

Comparability and quality of experimental data under different quality systems. S. Caroli Istituto Superiore di Sanità Rome Comparability and quality of experimental data under different quality systems S. Caroli Istituto Superiore di Sanità Rome Programme of this presentation Part I. Background information Part II. Key aspects

More information

NEPHROCHECK Calibration Verification Kit Package Insert

NEPHROCHECK Calibration Verification Kit Package Insert NEPHROCHECK Calibration Verification Kit Package Insert Manufactured for Astute Medical, Inc. 3550 General Atomics Ct. Building 2 San Diego, CA 92121 USA Intended Use The NEPHROCHECK Calibration Verification

More information